Skip to main content

Bioanalytical Methods to Reduce Drug Interference in Anti-Drug Antibody Assay

Bioanalytical Methods to Improve Drug Tolerance


1. Acid Dissociation
2. Solid-phase extraction with acid dissociation (SPEAD)
5. Precipitation and acid dissociation (PandA)

1. Acid Dissociation methods:

Acid-base treatment is a widely adopted dissociation method for improving the drug tolerance of the assay. The method is based on the principle that acid or base breaks any drug: antibody complex interaction thereby allowing the detection/capture reagents to the ADAs. 
The method involves incubation of ADA: drug complex with weak acid with pH 2-3 (e.g 300mM acetic acid, 0.1 mM Glycine) followed by neutralization with base (1 mM Tris HCl, pH 9.5), whereas if a high concentration of circulating drugs is present, there is a higher probability that ADA re-associates with the drug during the neutralization step. The acid may also negatively affect the assay signal/noise ratio and assay sensitivity. 
In those cases, an alternative sample extraction technique may be appropriate.

2. Solid-phase extraction with acid dissociation (SPEAD) method:


The solid-phase extraction and acid dissociation sample treatment method are performed in two steps: 
a) A biotin-avidin capture technique physically separates ADA and ADA-drug complexes from the sample matrix, which eliminates the excess unbound drug and other serum proteins that can interfere in the assay.  
b) The acid dissociation step removes the ADA from the biotin-avidin complex but does not dissociate the biotin-streptavidin bond. The high pH after neutralization encourages the binding of ADA and ADA: drug complex to the surface of a microtiter ELISA plate. The SPEAD treatment method has been shown to improve drug tolerance by 10-100 folds than without sample treatment while retaining the sensitivity of the assay. (Smith  et al. 2007)


3. Affinity Capture Elution (ACE) method:

The ACE method is based on the principle that acid treatment dissociates the ADA-drug complexes followed by neutralization in the solid-phase allowing ADA to be affinity captured. After washing excess drugs, ADA is diluted off with acid and subsequently bound to a fresh surface. Bound ADA are subsequently detected by the addition of biotinylated drug followed by streptavidin-HRP and substrate. (Bourdage et al., 2007). The ACE treatment method has been shown to improve drug tolerance up to 500 ug/ml while retaining the sensitivity of the assay below 500 ng/ml. (Click Here ACE Method in Details)

The recently described ACE- bridging assay format combines the affinity and capture step of ACE format followed by dual-labeled drug bridging of the bridging assay. Although bridging assay is highly sensitive but prone to interference by a high concentration of unlabeled drugs which competes with a labeled reagent for ADA binding. 
The ACE-bridging assay format overcomes the poor drug tolerance of the bridging assay by removing the excess drug. The ACE-bridging assay was able to tolerate high drug concentration while retaining the sensitivity of the assay below 100ng/ml. (Chen et al, 2016)

4. Biotin-Drug Extraction and Acid Dissociation (BEAD) method:

This method utilizes dissociation of ADA: drug complex with acid followed by biotin drug in neutralization buffer allowing the ADA to bind to the biotinylated drug. Biotinylated drug: ADA was extracted with streptavidin-coated magnetic beads. Second acid treatment of separated biotinylated drug: ADA( magnetic beads ) allows selective extraction of ADA from any residual drugs. 
This method was implemented in an accurate measurement of neutralizing antibodies in LC-MS format as well as cell-based NAb format (Jiang et al. 2014, Xu et al. 2015, Niu H et al. 2017). The step-wise procedure for optimization of BEAD method is described in a separate post (Click Here For  BEAD Method In Detail)

5. PandA method:

In the PandA method, the ADA: 
Free drug complex formed in the presence of the excess free drug is precipitation using PEG. The precipitates are treated with an acid to dissociate the free drug-ADA complex. The dissociated free ADA is captured onto the large capacity surface and detected using a specific detection agent. 
The assay with this treatment method was able to tolerate high drug concentration while retaining the sensitivity of the assay below 100 ng/ml. (Zoghbi et al, 2015)


Comments

Post a Comment

Popular posts from this blog

MCQs on Neisseria gonorrhoeae and Neisseria meningitidis: Medical microbiology

                                                       Multiple Choice Questions on Neisseria species (Gram-negative cocci) 1) A 19-year-old female college freshman, presented to the university health center with a severe headache, fever, and a stiff neck. She lived in a dormitory and was active in various social activities. She had received all her childhood vaccinations but had not received a booster for the meningococcal vaccine recommended before college entry. Clinical Presentation: On day 1, the patient experienced a sudden onset of fever (39.5°C or 103.1°F), severe headache, nausea, and vomiting. She also noticed a rash on her trunk and legs. Over the next two days, her symptoms deteriorated further, leading to photophobia and altered mental status. Concerned, her roommates brought her to the university health center. Physical Examinati...

Multiple Choice Questions (MCQs) on Diabetes Mellitus: Pathogenesis, Diagnosis and Treatment

                                        MCQs on Diabetes mellitus 1) Diabetes mellitus is a disorder characterized by hyperglycemia.  Which of the following is not the common characteristic features of type 2 diabetes mellitus ? a) Impaired insulin secretion b) Increased Insulin resistance  c) Diabetic ketoacidosis d) Excessive hepatic glucose production 2) Which of the following are the characteristic features of type 1 diabetes mellitus? a) Type 1 diabetes is caused by an absolute deficiency of insulin. b) Type 1 diabetes is associated with the autoimmune destruction of beta cells.  c) Patients with  uncontrolled type 1 diabetes present with diabetic ketoacidosis d) All of the above   3) Which of the following serum measurements are not used for the diagnosis of diabetes mellitus? a) Fasting blood glucose d) Postprandial blood glucose  c) Insulin ...

Pentose Phosphate Pathway: Source of NADPH for Reductive Biosynthesis (Biochemistry)

Introduction to Pentose Phosphate Pathway The pentose phosphate pathway ( Hexose monophosphate pathway ) is the metabolic pathway that occurs in the cytosol and generates NADPH (nicotinamide adenine dinucleotide phosphate) which is utilized in various biosynthetic pathways. This pathway can be broadly classified into two phases i.e oxidative phase and non-oxidative phase.  In the oxidative stage of the pentose phosphate pathway, the glucose-6-phosphate is converted to five carbon ribulose-5 phosphate with generation of NADPH.  During the non-oxidative stage, the interconversion of pentose sugars and hexose sugars is catalyzed by isomerases and aldolases. The fate of these reversible steps depends on the anabolic and energy status of the cells.  The two primary functions of the pentose phosphate pathway are ; a) Provide NADPH (a coenzyme) for biosynthetic pathways b) Provide pentose sugars for nucleotides (DNA and RNA) synthesis Two phases of Pentose phosphat...